Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06070350 · ClinicalTrials.gov registry record · Phase 3

Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children

A Phase 3 study of Trauma Injury and Hemorrhagic Shock, sponsored by Philip Spinella.

Recruiting
Registry status
Phase 3
Development phase
1,000
Enrollment target
20
Study locations

NCT06070350: Recruiting Phase 3 study of Trauma Injury and Hemorrhagic Shock, sponsored by Philip Spinella.

NCT06070350 is a Phase 3 study of Trauma Injury and Hemorrhagic Shock that is actively recruiting participants, run by Philip Spinella. The registered enrollment target is 1,000 participants, above the 434-participant average among 15 other Trauma Injury trials with a reported enrollment target (130% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06070350, a Phase 3 study of Trauma Injury and Hemorrhagic Shock, is actively recruiting participants, sponsored by Philip Spinella.

RECRUITING
Registry status
Phase 3
Development phase
1,000 participants
Enrollment target
20
Study locations

Study Summary

The MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of age with hemorrhagic shock potentially needing significant blood transfusion. The primary objective of the clinical trial is to determine the effectiveness of Low Titer Group O Whole Blood (LTOWB) compared to component therapy (CT), and Tranexamic Acid (TXA) compared to placebo in decreasing 24-hour all-cause mortality in children with traumatic life threatening hemorrhage.

Conditions Studied

Trauma Injury Hemorrhagic Shock

Interventions

  • DRUG Placebo
  • DRUG Tranexamic Acid (TXA)
  • BIOLOGICAL Low Titer Group O Whole Blood (LTOWB)
  • BIOLOGICAL Component Therapy (CT)

Study Locations (20)

Texas

  • The University of Texas Southwestern Medical Center - Dallas
  • Baylor College of Medicine - Houston
  • Children's Memorial Hermann Hospital - Houston
  • University of Texas Health Science Center at San Antonio - San Antonio

Georgia

  • Emory University-Arthur M. Blank Hospital - Atlanta
  • Emory University-Scottish Rite Hospital - Atlanta

Tennessee

  • LeBonheur Children's Hospital - Memphis
  • Vanderbilt University Medical Center - Nashville

Arizona

  • University of Arizona - Tucson

Arkansas

  • Arkansas Children's Hospital - Little Rock

California

  • University of California Davis - Sacramento

District of Columbia

  • Children's National Hospital - Washington D.C.

Louisiana

  • Tulane School of Medicine - New Orleans

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2024-11-01
Est. Completion 2028-10-01
Phase Phase 3
Philip Spinella

2 total trials

What NCT06070350 shows while recruiting

NCT06070350 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 434-participant average among 15 other Trauma Injury trials with a reported enrollment target (130% higher).

The record links to 2 conditions, with Trauma Injury appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT06070350 names 20 study sites across 15 states, led by Texas, Georgia, Tennessee.

Frequently Asked Questions

What is clinical trial NCT06070350 about?

NCT06070350 is a clinical study titled "Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children". The MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of age with hemorrhagic shock potentially needing significant blood transfusion. The primary objective of the clinical trial is to determine the effectiveness of Low Titer Group O Whole Blood (LTOWB) compared ...

What is the current status of trial NCT06070350?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2024-11-01. Estimated completion is 2028-10-01.

What conditions does trial NCT06070350 study?

This clinical trial studies the following conditions: Trauma Injury, Hemorrhagic Shock.

What interventions are being tested in trial NCT06070350?

The interventions under investigation include: Placebo (DRUG), Tranexamic Acid (TXA) (DRUG), Low Titer Group O Whole Blood (LTOWB) (BIOLOGICAL), Component Therapy (CT) (BIOLOGICAL).

Who is sponsoring clinical trial NCT06070350?

This trial is sponsored by Philip Spinella, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06070350 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Trauma Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06070350's enrollment target sits among peer trials

1,000 3rd of 15 higher than 12 of 15 other Trauma Injury trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Trauma Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00018044 · 1,000 participants

    Study of Mycobacterial Infections

  • NCT01036581 · 1,000 participants · NA

    Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

  • NCT01192048 · 1,000 participants

    Genetics of Congenital Heart Disease

  • NCT01553214 · 1,000 participants · Phase 4

    Improving White Blood Cell Collection From Healthy Donors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06070350

Source: ClinicalTrials.gov NCT06070350, the US trial registry maintained by the National Library of Medicine. NCT06070350 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.